Nov 9, 2012 | Laboratory News, Laboratory Operations, Laboratory Pathology, Management & Operations
UnitedHealth’s acquisition of Brazil’s Amil is another example of healthcare’s globalization and may open door for clinical laboratory acquisitions in Brazil
UnitedHealth Group (NYSE: UNH) is buying an HMO in Brazil. The two players are the largest insurers in their respective countries. For pathologists and clinical laboratory professionals, this merger demonstrates that the trend toward globalization of healthcare—including laboratory medicine—continues one step at a time.
Brazil’s Growing Middle Class Drives Demand for Coverage
On October 8, 2012, UnitedHealth announced in a press release that it would pay $4.9 billion in cash to acquire a 90% stake in Brazil’s Amil Participacoes S.A. (BM&FBOVESPA: AMIL3). Amil is Brazil’s largest private insurer and operator of health clinics. The company provides health benefits and services to more than five million people. (more…)
Feb 8, 2012 | Laboratory Management and Operations, Laboratory News, Laboratory Pathology, Managed Care Contracts & Payer Reimbursement
Many physicians say they lack specific details about the care model and how it will reimburse providers
In its own news service, the American Medical Association (AMA) reports lagging interest by physicians when they are asked about their participation in accountable care organizations (ACO). This survey of AMA members was conducted last fall.
According to an article at amednews.com (AMN), this survey found that—although many physicians are familiar with the concept—a significant number of them indicate they will either opt out of an ACO or unsure whether they will participate in an ACO.
(more…)
Nov 14, 2011 | Compliance, Legal, and Malpractice, Laboratory News, Laboratory Pathology, Laboratory Sales and Marketing
Two Senate committees seem interested in how certain medical laboratories offer discounted laboratory test prices to selected health insurers
Is it a coincidence that discounted medical laboratory test pricing offered by the nation’s two largest clinical laboratory companies appears to now be the subject of interest for the Senate Judiciary and Senate Finance Committees? Last Tuesday, Senator Max Baucus (D-Montana) and Senator Chuck Grassley (R-Iowa) issued a press release titled “Grassley, Baucus Scrutinize Practice by Health Insurers and Testing Labs.”
Baucus is Chairman of the Senate Finance Committee and Grassley is the Ranking Member of the Senate Judiciary Committee. Together, these two Senators sent letters last week to two clinical laboratory companies and three big health insurance firms: (more…)
Apr 4, 2011 | Digital Pathology, Laboratory News, Laboratory Pathology
Experts at National Comprehensive Cancer Network conference voice opinions
It may surprise many pathologists and clinical laboratory managers to learn that a number of prominent healthcare leaders recently voiced significant reservations about the current status of molecular genetics testing. In their view, clinical pathology laboratory testing that incorporates genetic and molecular technologies needs further refinement, improved billing codes, and additional regulation before it can fulfill its potential to be a precise diagnostic tool.
That was the conclusion reached by a panel of distinguished physicians representing healthcare organizations, pharmaceutical giants, insurance companies, and the government at this year’s annual National Comprehensive Cancer Network (NCCN) conference.
(more…)
Feb 9, 2011 | Digital Pathology, Laboratory Instruments & Laboratory Equipment, Laboratory Pathology
Pathologists take note: 80% of physicians will be using mobile technology by 2012
Meet “mHealth!” That’s the new term to describe how mobile devices are used in the delivery of healthcare to patients. Many clinical laboratories and pathology groups already have laboratory informatics solutions that support how their client physicians use mHealth solutions in patient care.
Experts predict that Smartphones will dominate mobile healthcare (mHealth) in just a few short years. The enabling tools will be mobile applications (apps) that monitor such conditions as diabetes, hypertension, coronary heart disease and asthma. Smart phones will also be used to order medical laboratory tests and access clinical laboratory test data.
(more…)
